Korean biotechs license drugs to US and global partners. The terms are disclosed in Korea; the events that move them are disclosed by the partner. This page links both, with the exact sources.
Milestones for the initial licensed product: up to US$111 million (development and regulatory) and up to US$225 million (sales); ORIC to pay US$5 million in cash and issue 283,259 shares[1]
Latest partner event
Date not disclosed
VRN07 entered an overseas Phase 1 trial, as a Voronoi official explained the milestone[2]
Latest payment announcement
Disclosed
Voronoi disclosed that it received a KRW 6.5 billion milestone[2]
Next timing stated by the partner
We expect to report data in the second half of 2026 in 1L NSCLC patients with EGFR exon 20 insertion mutations as a monotherapy and in combination with SC amivantamab, as well as in 1L NSCLC patients with EGFR atypical mutations as a monotherapy.[3]
Full record (7 items)
Disclosed terms
In exchange for the license, ORIC agreed to make a one-time payment of $5 million in cash and issue 283,259 shares of its common stock[1]
Milestones: up to $111 million in development and regulatory milestones and up to $225 million in sales milestones with respect to the first licensed product[1]
Maximum milestones of US$621 million (about KRW 820 billion), as Voronoi signed the contract[2]
Partner event:Date not disclosedVRN07 entered an overseas Phase 1 trial, as a Voronoi official explained the milestone[2]
Payment announcement:Disclosed Voronoi disclosed that it received a KRW 6.5 billion milestone[2]
Payment announcement:Q3 2022ORIC reported: In the third quarter of 2022, the Company made a development milestone payment to Voronoi in the amount of $ 5.0 million[3]
Sources
ORIC Pharmaceuticals Form 8-K, dated 2020-10-19: sec.gov
Upfront US$30 million, R&D funding up to US$20 million and milestones of US$452.5 million (total US$502.5 million); per Immunovant’s 10-K, up to US$420.0 million in contingent payments tied to regulatory and sales milestones[1][3]
Latest partner event
Quarter ended June 30, 2023
Immunovant reported that During the quarter ended June 30, 2023, the Company achieved its third and fourth development and regulatory milestone events under the HanAll Agreement[3]
Latest payment announcement
Quarter ended September 30, 2023
of $ 12.5 million, combined, which was paid in the quarter ended September 30, 2023[3]
Next timing stated by the partner
In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG.[4]
R&D funding up to US$20 million (about KRW 21.6 billion), over five years[1]
Milestones of US$452.5 million, tied to clinical stages, approval, added indications and sales targets[1]
Total US$502.5 million (about KRW 544.9 billion)[1]
Immunovant’s 10-K: In December 2018, we obtained and assumed all of the rights, title, interest and future obligations under the HanAll Agreement from RSG, including all rights to IMVT-1402 and batoclimab in the Licensed Territory[3]
Licensed Territory: the U.S., Canada, Mexico, the EU, the UK, Switzerland, the Middle East, North Africa and Latin America[3]
Remaining payments, per the 10-K: we will be responsible for future contingent payments and royalties, including up to an aggregate of $420.0 million upon the achievement of certain regulatory and sales milestone events[3]
Partner event:Date not disclosedStart of the global Phase 3 trial of HL161 in myasthenia gravis, as stated in HanAll's disclosure[2]
Payment announcement:HanAll disclosed that it will receive US$10 million (KRW 13.2 billion) from Roivant Sciences[2]
Event and payment 2 of 2
Partner event:Quarter ended June 30, 2023Immunovant reported that During the quarter ended June 30, 2023, the Company achieved its third and fourth development and regulatory milestone events under the HanAll Agreement[3]
Payment announcement:Quarter ended September 30, 2023of $ 12.5 million, combined, which was paid in the quarter ended September 30, 2023[3]
Partner event:Reported Johnson & Johnson announced US FDA approval of Rybrevant with Leclaza for non-small cell lung cancer[2]
Payment announcement:Reported Yuhan will receive a US$60 million milestone (about KRW 80.07 billion) and royalties on future sales[2]
Event and payment 2 of 2
Partner event:Date not disclosedStart of commercialization in Europe (date not stated). The European Commission approved the Leclaza and Rybrevant combination in December 2024[3]
Payment announcement:Disclosed Yuhan disclosed that it will receive US$30 million (KRW 44.9 billion)[3]
Exclusive license for the Keytruda product family with ALT-B4 after the amendment; maximum milestones US$4.298 billion[1]
Latest partner event
Date not disclosed
European marketing approval of Keytruda SC (date not stated)[3]
Latest payment announcement
Announced
Alteogen said it will receive a US$15 million milestone (about KRW 21.94 billion)[3]
Full record (9 items)
Disclosed terms
The amendment made the license exclusive for the Keytruda product family developed with ALT-B4; other products stay non-exclusive[1]
Alteogen disclosed that it will receive an additional US$20 million (about KRW 26.7 billion) with the amendment[1]
Maximum milestones raised by US$432 million to US$4.298 billion (about KRW 5.7 trillion). Before the amendment, the maximum was US$3.865 billion for approval, patent-extension and cumulative-sales milestones[1]
Up to US$700 million in upfront, R&D and sales milestones, plus royalties on net sales[1]
Latest partner event
June 2026 (month of the announcement)
Ono Pharmaceutical announced last month that it had begun enrolling patients in a Phase 1 clinical trial of LCB97.[2]
Latest payment announcement
Disclosed
LigaChem Biosciences said in a regulatory filing on the 9th that the milestone payment triggered by the first patient dosing of LCB97 has been confirmed.[2]
Full record (5 items)
Disclosed terms
Up to US$700 million (about KRW 943.5 billion) in upfront, R&D and sales milestones, plus royalties on net sales[1]
Partner event:June 2026 (month of the announcement)Ono Pharmaceutical announced last month that it had begun enrolling patients in a Phase 1 clinical trial of LCB97.[2]
Payment announcement:Disclosed LigaChem Biosciences said in a regulatory filing on the 9th that the milestone payment triggered by the first patient dosing of LCB97 has been confirmed.[2]
Payment announcement:Date not disclosedAmount: The exact amount is confidential under the contract, but it corresponds to more than 10% of the company's consolidated revenue of 141.55307 billion won last year.[2]
Upfront US$75 million; up to US$985 million in milestones; total US$1.06 billion[1]
Latest partner event
Announced
ABL Bio completed the manufacturing technology transfer of ABL301 to Sanofi[3]
Latest payment announcement
Announced
ABL Bio will receive a US$5 million milestone (about KRW 7 billion)[3]
Full record (8 items)
Disclosed terms
ABL Bio said it will receive $75 million in upfront payments and is eligible to receive up to $985 million based on the achievement of commercialization milestones, including $45 million in near-term milestones.[1]
ABL Bio said it will lead the preclinical development and phase 1 clinical trial of ABL301, while Sanofi will be responsible for subsequent clinical trials, regulatory approval and global commercialization.[1]
Yuhan disclosed that it was notified of the termination of the license and the return of rights. The US$40 million upfront and the US$10 million milestone it received are not refundable[3]
Latest payment announcement
Announced
Yuhan will receive a US$10 million (KRW 12 billion) fee[2]
Full record (6 items)
Disclosed terms
Upfront US$40 million, non-refundable (about KRW 45 billion); US$10 million of it after the non-clinical toxicity study[1]
Partner event:Announced Yuhan said Boehringer Ingelheim had started a Phase 1 trial of YH25724 in Europe[2]
Payment announcement:Announced Yuhan will receive a US$10 million (KRW 12 billion) fee[2]
Later disclosure
Disclosed Yuhan disclosed that it was notified of the termination of the license and the return of rights. The US$40 million upfront and the US$10 million milestone it received are not refundable[3]
Exclusive US and Canada sales rights; upfront US$2.5 million; up to US$537.5 million in clinical, regulatory and sales milestones[1]
Latest partner event
Braintree Laboratories announced that it submitted a New Drug Application (NDA) on January 9, 2026 to the U.S. Food and Drug Administration (FDA) for tegoprazan[2]
Partner event:Braintree Laboratories announced that it submitted a New Drug Application (NDA) on January 9, 2026 to the U.S. Food and Drug Administration (FDA) for tegoprazan[2]
Joint development; worldwide rights shared equally, excluding Greater China and South Korea[1]
Latest partner event
June 2026
In June 2026, the FDA granted Fast Track Designation to givastomig for the treatment of previously untreated HER2-negative advanced or metastatic GEA in combination with nivolumab and chemotherapy.[1]
Latest payment announcement
No announcement found.
Next timing stated by the partner
NovaBridge expects to initiate a Phase 3 registrational study under a potential Accelerated Approval Pathway as early as year end 2026.[1]
Full record (3 items)
Disclosed terms
Givastomig is being jointly developed through a global partnership with ABL Bio, Inc. (“ABL Bio”). NovaBridge is the lead party and shares worldwide rights equally with ABL Bio, excluding Greater China and South Korea.[1]
Partner events and payment announcements
Event and payment
Partner event:February 2026In February 2026, NovaBridge initiated a global, randomized Phase 2 study of givastomig combined with immunochemotherapy in patients with HER2-negative, 1L metastatic gastric cancer.[1]
Partner event:June 2026In June 2026, the FDA granted Fast Track Designation to givastomig for the treatment of previously untreated HER2-negative advanced or metastatic GEA in combination with nivolumab and chemotherapy.[1]
Sources
NovaBridge Biosciences Form 6-K, Exhibit 99.1, filed 2026-08-20: sec.gov
Worldwide rights outside Korea; upfront: US$22 million in NeuroBo convertible preferred stock to Dong-A ST; development milestones up to US$316 million[1]
Latest partner event
April 2026
April 2026: Dosed the first patient in Part 3 of the 16-week Phase 1 clinical trial evaluating DA-1726 in obese, otherwise healthy adults[2]
Latest payment announcement
No announcement found.
Next timing stated by the partner
Data readout from Phase 1 Part 3, 16-week titration studies, evaluating titration to 48 mg in one step and 64 mg via a two-step regimen, is expected in the fourth quarter of 2026.[2]
Full record (5 items)
Disclosed terms
Worldwide development and sales rights outside Korea for DA-1241 and DA-1726[1]
Upfront: US$22 million in NeuroBo convertible preferred stock[1]
Partner event:April 2026April 2026: Dosed the first patient in Part 3 of the 16-week Phase 1 clinical trial evaluating DA-1726 in obese, otherwise healthy adults[2]
Partner event:Announced Spectrum today announced that the U.S. Food and Drug Administration (FDA) has approved ROLVEDON ™ (eflapegrastim-xnst) injection[1]
Sources
Spectrum Pharmaceuticals Form 8-K, Exhibit 99.1, filed 2022-09-12: sec.gov
Upfront US$10 million; milestones up to US$860 million; royalties on sales[1]
Latest partner event
No announcement found.
Latest payment announcement
No announcement found.
Full record (2 items)
Disclosed terms
Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide, as well as double-digit royalties on sales of approved product.[1]
Asset acquisition: upfront US$100 million; total deal value US$180 million[1]
Latest partner event
Disclosed
Orum disclosed that the asset transfer agreement ended after BMS stopped development of BMS-986497 (ORM-6151). The US$100 million upfront it received is not returned; the US$80 million in development milestones will not be received[2]
Latest payment announcement
No announcement found.
Full record (5 items)
Disclosed terms
Under this transaction, Bristol Myers Squibb has acquired Orum’s ORM-6151 program for an upfront payment of $100 million, and Orum Therapeutics is eligible to receive milestone payments for a total deal value of $180 million.[1]
Partner event:Date not disclosedBMS began a global Phase 1 trial of ORM-6151 (date not stated), then decided to stop further development after reviewing the clinical data[2]
Later disclosure
Disclosed Orum disclosed that the asset transfer agreement ended after BMS stopped development of BMS-986497 (ORM-6151). The US$100 million upfront it received is not returned; the US$80 million in development milestones will not be received[2]
Partner side: SEC filings and partner releases. Korean side: Korean press reports of the companies’ DART filings (BioSpectator, BizWatch, Dailypharm, Dealsite, Korea JoongAng Daily, Medigate News, Seoul Economic Daily, English edition (marked AI-translated from Korean), The Korea Economic Daily Global Edition (KED Global)).
Korean-side figures are currently from press reports of DART filings. Links to the DART originals will follow.
Amounts are shown as each source reports them, with its own KRW conversion. Text in quotation marks is copied from the source; the rest is ORION’s English summary of the cited page. Each bracketed number opens the card’s source list.
Dates are the announcement or disclosure dates the sources give, unless a source states the event date itself.
A day count between an event and its payment appears where both have exact dates from separate announcements. Where they were announced together, or the event date is not disclosed or is given as a month or quarter, no day count is shown.
Status chips repeat what a cited fact states; each has its source number.
“No announcement found” means none was found in the sources listed on this page.
Checked on .
No predictions. ORION does not say whether a milestone will be paid.